Because administration of 5-Aza-dc attenuates atherosclerosis in Ldlr−/− mice [55], it is tempting to speculate that a combined regimen consisting of a DNMT inhibitor and a SIRT6 activator could be considered a novel therapeutic solution for patients with CHD. This evidence concerns the gene SIRT6 and coronary artery disorder.